Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia.

Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A.

J Neurovirol. 2018 Feb;24(1):132-136. doi: 10.1007/s13365-017-0605-1. Epub 2017 Dec 14.

2.

Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.

Mukerji SS, Misra V, Lorenz D, Cervantes-Arslanian AM, Lyons J, Chalkias S, Wurcel A, Burke D, Venna N, Morgello S, Koralnik IJ, Gabuzda D.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):246-255. doi: 10.1097/QAI.0000000000001362.

3.
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques.

Queen SE, Mears BM, Kelly KM, Dorsey JL, Liao Z, Dinoso JB, Gama L, Adams RJ, Zink MC, Clements JE, Kent SJ, Mankowski JL.

J Virol. 2011 Sep;85(17):9167-75. doi: 10.1128/JVI.00366-11. Epub 2011 Jun 29.

6.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
7.

Brain MRI Features of CSF Human Immunodeficiency Virus Escape.

Narvid J, Callen A, Talbott J, Uzelac A, Dupont SM, Chow F, Price RW, Rehani B.

J Neuroimaging. 2018 Nov;28(6):601-607. doi: 10.1111/jon.12552. Epub 2018 Aug 5.

PMID:
30079471
8.

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, Cinque P, Spudich S.

AIDS. 2012 Sep 10;26(14):1765-74. doi: 10.1097/QAD.0b013e328355e6b2.

9.

Viral escape in the CNS with multidrug-resistant HIV-1.

Béguelin C, Vázquez M, Bertschi M, Yerly S, de Jong D, Rauch A, Cusini A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19745. doi: 10.7448/IAS.17.4.19745. eCollection 2014.

10.

Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.

Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, Morelli P, Carrera P, Ferrari M, Lazzarin A.

AIDS Res Hum Retroviruses. 2001 Mar 20;17(5):377-83.

PMID:
11282006
11.

HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.

Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, Wu X, Mascola JR.

J Virol. 2015 Apr;89(8):4201-13. doi: 10.1128/JVI.03608-14. Epub 2015 Jan 28.

12.

Neurosymptomatic cerebrospinal fluid escape in HIV-2: a case report.

Kulkarni V, Kulkarni R, Parchure R.

Int J STD AIDS. 2018 Jun;29(7):726-728. doi: 10.1177/0956462417749421. Epub 2017 Dec 17.

PMID:
29251118
13.

Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control.

Caetano DG, Côrtes FH, Bello G, Teixeira SLM, Hoagland B, Grinsztejn B, Veloso VG, Guimarães ML, Morgado MG.

Retrovirology. 2018 Sep 10;15(1):62. doi: 10.1186/s12977-018-0444-z.

14.

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Gisslén M.

J Infect Dis. 2010 Dec 15;202(12):1819-25. doi: 10.1086/657342. Epub 2010 Nov 4.

15.

HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape.

Bingham R, Ahmed N, Rangi P, Johnson M, Tyrer M, Green J.

Int J STD AIDS. 2011 Oct;22(10):608-9. doi: 10.1258/ijsa.2011.010507.

PMID:
21998185
16.

CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.

Calcagno A, Barco A, Trunfio M, Bonora S.

Curr HIV/AIDS Rep. 2018 Feb;15(1):84-91. doi: 10.1007/s11904-018-0375-2. Review.

PMID:
29363025
17.

Cerebrospinal fluid HIV RNA in persons living with HIV.

Di Carlofelice M, Everitt A, Muir D, Winston A.

HIV Med. 2018 May;19(5):365-368. doi: 10.1111/hiv.12594. Epub 2018 Jan 25.

18.

Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.

Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A, Bonora S.

Clin Infect Dis. 2015 Jan 15;60(2):311-7. doi: 10.1093/cid/ciu773. Epub 2014 Oct 3.

19.

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.

Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD, Rosenberg ES.

J Immunol. 2003 Apr 1;170(7):3906-14.

20.

Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.

Motta I, Allice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, Ghisetti V, Di Perri G, Bonora S, Calcagno A.

Antivir Ther. 2017;22(6):539-543. doi: 10.3851/IMP3140. Epub 2017 Feb 15.

Supplemental Content

Support Center